[New development lines in immunology. Perspective of pathology].

about

[New development lines in immunology. Perspective of pathology].

Item

http://www.wikidata.org/entity/Q54397306

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

[New development lines in immunology. Perspective of pathology].

@en

[New development lines in immunology. Perspective of pathology].

@nl

type

Item

label

[New development lines in immunology. Perspective of pathology].

@en

[New development lines in immunology. Perspective of pathology].

@nl

prefLabel

[New development lines in immunology. Perspective of pathology].

@en

[New development lines in immunology. Perspective of pathology].

@nl

P1476

[New development lines in immunology. Perspective of pathology].

@en

P2093

D Zielinski

http://www.w3.org/2001/XMLSchema#string

E Heinmöller

http://www.w3.org/2001/XMLSchema#string

J Rüschoff

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung.

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients

Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification

From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Microfluidic processor allows rapid HER2 immunohistochemistry of breast carcinomas and significantly reduces ambiguous (2+) read-outs.

Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.

Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice.

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.

P2888

s00292-013-1811-0

P304

226-229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00292-013-1811-0

http://www.w3.org/2001/XMLSchema#string

P407

Af-Jarmal

P478

34 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24196618

http://www.w3.org/2001/XMLSchema#string